MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Eligible age
6–23 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastography (MREL), as non-invasive biomarkers to assess two primary pathophysiological processes of AILD: bile duct damage and liver fibrosis. In this cross-sectional study MRI based findings of bile duct injury and liver fibrosis will be correlated with both liver histology and circulating biomarkers of these disease processes.
Sponsor: Children's Hospital Medical Center, Cincinnati
You may qualify if…
- ✓ 1. Age 6-23 years old.
- ✓ 2. Established or suspected clinical diagnosis of AIH or PSC.
You may not qualify if…
- ✕ 1. History of liver transplantation.
- ✕ 2. Chronic Hepatitis B or untreated hepatitis C virus infection.
- ✕ 3. Pregnancy.
- ✕ 4. Absolute contraindication for MRI (e.g. pacemaker, metallic implants, claustrophobia).
- ✕ 5. Diagnosis of cystic fibrosis or biliary atresia
- ✕ 6. Diagnosis of cardiac hepatopathy.
- ✕ 7. Diagnosis of Wilson's disease, Alpha-1 Antitrypsin deficiency, or Glycogen storage disease.
- ✕ 8. Skin conditions which could be aggravated by MREL (i.e. Epidermolysis bullosa).
Where it's recruiting
Cincinnati
Source: ClinicalTrials.gov · NCT03175471 · last updated 2024-12-12